Dermata Therapeutics (DRMA)
NASDAQ:DRMA
Want to see DRMA full AI Analyst Report?
Top Page
Dermata Therapeutics
(NASDAQ:DRMA)
Select Model
Select Model
Rating:45Neutral
Price Target:
$1.00
▼(-53.27% Downside)
Action:Reiterated
Date:05/28/26
The score is primarily held down by weak financial performance (no revenue, ongoing losses and cash burn) despite the benefit of no debt and some recent improvement. Technicals add mild downside bias with the stock trading below key moving averages, while valuation offers limited support due to negative earnings and no dividend. Corporate actions improve financing flexibility but highlight dilution and funding dependency risks.
Positive Factors
Debt-free balance sheet
A lack of debt is a durable financial strength for a clinical-stage biotech: it lowers fixed obligations, reduces bankruptcy risk, and preserves flexibility to time external financings or partnerships. This structural cushion supports R&D continuity through development milestones.
Negative Factors
Pre-revenue status
Being pre-revenue is a fundamental constraint: without product sales the company must rely on funding events to advance development. This structural absence of recurring revenue delays any internal generation of operating cash and makes long-term sustainability contingent on successful commercialization or continuing financings.
Read all positive and negative factors
Positive Factors
Negative Factors
Debt-free balance sheet
A lack of debt is a durable financial strength for a clinical-stage biotech: it lowers fixed obligations, reduces bankruptcy risk, and preserves flexibility to time external financings or partnerships. This structural cushion supports R&D continuity through development milestones.
Read all positive factors
Dermata Therapeutics (DRMA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$4.75M
Dividend YieldN/A
Average Volume (3M)249.42K
Price to Earnings (P/E)―
Beta (1Y)1.13
Revenue GrowthN/A
EPS Growth93.30%
CountryUS
Employees8
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-5.31
Shares Outstanding4,022,143
10 Day Avg. Volume611,626
30 Day Avg. Volume249,418
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.35
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market Cap-1.28
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda0.82
Forecast
1Y Price Target
$4.00Price Target Upside86.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.21
Revenue Forecast (FY)$15.00M
Dermata Therapeutics Business Overview & Revenue Model
Company Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product ca...
How the Company Makes Money
null...
Dermata Therapeutics Financial Statement Overview
Summary
Income Statement
12
Very Negative
Balance Sheet
46
Neutral
Cash Flow
18
Very Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -7.36M | -7.77M | -12.29M | 247.22K | -9.61M | -7.86M |
| Net Income | -7.10M | -7.56M | -12.29M | -7.79M | -9.61M | -7.90M |
Balance Sheet | ||||||
| Total Assets | 7.47M | 7.86M | 3.53M | 7.98M | 6.94M | 11.62M |
| Cash, Cash Equivalents and Short-Term Investments | 6.95M | 7.52M | 3.16M | 7.44M | 6.24M | 10.80M |
| Total Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Liabilities | 1.05M | 1.64M | 1.97M | 1.62M | 922.63K | 1.52M |
| Stockholders Equity | 6.41M | 6.22M | 1.56M | 6.36M | 6.02M | 10.11M |
Cash Flow | ||||||
| Free Cash Flow | -8.30M | -7.76B | -11.16M | -6.41M | -8.83M | -5.69M |
| Operating Cash Flow | -8.30M | -7.76B | -11.16M | -6.41M | -8.83M | -5.69M |
| Investing Cash Flow | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financing Cash Flow | 5.53M | 12.12B | 6.89M | 7.61M | 4.28M | 15.96M |
Dermata Therapeutics Technical Analysis
Negative
2.14
Price Trends
1.27
Negative
1.46
Negative
2.64
Negative
Market Momentum
>-0.01
Positive
41.95
Neutral
24.35
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For DRMA, the sentiment is Negative. The current price of 2.14 is above the 20-day moving average (MA) of 1.25, above the 50-day MA of 1.27, and below the 200-day MA of 2.64, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 41.95 is Neutral, neither overbought nor oversold. The STOCH value of 24.35 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for DRMA.
Dermata Therapeutics Risk Analysis
Dermata Therapeutics disclosed 87 risk factors in its most recent earnings report. Dermata Therapeutics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Dermata Therapeutics Peers Comparison
UnderperformOutperform
Sector (51)
DRMA
Dermata Therapeutics
1.18
-6.40
-84.43%
REVB
Revelation Biosciences
0.99
-9.39
-90.46%
CERO
CERo Therapeutics Holdings
0.01
-7.99
-99.85%
PBM
Psyence Biomedical
3.51
-30.21
-89.59%
AZTR
Azitra Inc
0.21
-1.72
-89.07%
Dermata Therapeutics Corporate Events
Business Operations and StrategyExecutive/Board ChangesPrivate Placements and FinancingShareholder Meetings
Dermata Therapeutics Shareholders Approve Equity Plan and Directors
Positive
May 27, 2026
On May 27, 2026, Dermata Therapeutics held its 2026 Annual Meeting of Stockholders, where shareholders approved an amendment to the company’s 2021 Omnibus Equity Incentive Plan, increasing the shares available for issuance to 402,214 and rea...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.